In addition, we used shRNA and obtained results consistent with two the inhibitors, supporting the notion that CD133+ tumor cells preferentially activate the p38MAPK-MAPKAPK2-Hsp27 pathway probably through suppression of PP2A to inhibit caspase 9 and 3 cleavage. The gene discussed is PROM1; the disease is neoplasm.